Integrated DNA Technologies Expands Synthetic Biology Portfolio Through Strategic Collaboration with Ansa Biotechnologies
Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics, has announced a strategic collaboration with Ansa Biotechnologies, Inc., a pioneering company in DNA synthesis. This partnership brings together two innovative forces in synthetic biology, enabling researchers worldwide to access new capabilities for designing and assembling longer, more complex DNA constructs.
Through this collaboration, Ansa Biotechnologies’ Clonal DNA and XL Clonal DNA products—ranging from 100 base pairs to 50 kilobases—will now be available to IDT customers. These products support a wide range of applications, including next-generation cell and gene therapy development, vaccine research, and agrigenomics studies. By combining IDT’s nearly 40-year legacy of quality, service, and global reach with Ansa’s cutting-edge enzymatic DNA synthesis technology, the collaboration aims to accelerate the delivery of challenging motifs, high-complexity constructs, and longer sequences with unmatched precision.
The partnership is designed to establish a new benchmark in speed, accuracy, and reliability. Each DNA sequence is rigorously verified and optimized for critical parameters such as GC content, homopolymers, and repetitive elements, ensuring researchers can rely on the integrity of their designs. This level of quality helps minimize troubleshooting, reduces rework, and lowers downstream risks, allowing scientists to focus on discovery rather than overcoming technical hurdles.
“Customers face unprecedented complexity in their research, and they deserve solutions that make progress simpler and faster,” said Ajay Gannerkote, President of IDT. “Our partnership with Ansa combines the reliability and trust our customers expect with innovative approaches in synthetic biology. This collaboration ensures that researchers can rely on IDT for their needs across all levels of complexity, enabling breakthroughs that truly matter.”
Jason T. Gammack, Chief Executive Officer of Ansa Biotechnologies, added: “Ansa was founded to tackle the toughest challenges in DNA synthesis: length, complexity, and reliability. Working with IDT, we are removing longstanding technical barriers and empowering researchers worldwide to explore new scientific frontiers with confidence and without compromise.”
Ansa’s proprietary enzymatic DNA synthesis platform is redefining what is possible in synthetic biology. It allows for the creation of longer and more complex DNA sequences while maintaining high fidelity, enabling the assembly of critical constructs at scale. The platform also embraces a sustainable approach, eliminating the use of harsh chemicals that can compromise DNA integrity. All Ansa DNA products are manufactured exclusively in the United States, ensuring consistent quality and compatibility with existing laboratory workflows. The company operates under a rigorous biosecurity framework and fully complies with the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening, reflecting its commitment to responsible innovation.
This collaboration allows IDT customers to seamlessly access Ansa’s Clonal DNA and XL Clonal DNA products through IDT’s online portal at www.idtdna.com/complexDNA, making advanced synthetic biology tools more accessible than ever.
About Integrated DNA Technologies
Integrated DNA Technologies (IDT) has evolved from its origins as an oligonucleotide manufacturer to become a leading global genomics provider. With a foundation built on innovation, expertise, and reliability, IDT partners closely with scientific institutions and global health organizations to advance genomics research at scale. The company’s mission is to empower researchers to move from the lab to life-changing discoveries quickly, supporting a healthier, brighter future for all.
IDT is a proud member of the Danaher family, a global science and technology leader dedicated to accelerating the impact of science and technology on human health. Learn more about Danaher’s commitment to innovation in life sciences and diagnostics at www.Danaher.com.
Through this strategic collaboration, IDT and Ansa Biotechnologies are advancing the frontier of synthetic biology, providing researchers with the tools and confidence to tackle increasingly complex scientific challenges and unlock the next generation of breakthroughs.
Source link : https://www.businesswire.com/
